

UNITED STATE DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATT	ORNEY DOCKET NO.
09/524,53	1 03/13/00	IMHOF		В	FM 264679
FILLSBURY WINTHROF 1600 TYSONS BOULEV MCLEAN VA 22102			٦	EXAMINER RUARK, J	
	22102			ART UNIT 1644	PAPER NUMBER
				DATE MAILED:	09/07/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

BEST AVAILABLE COPY

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.usolo.gov

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
09/524,531				
				EXAMINER
		·	K	Poarle
			ART UNIT	PAPER
			1644	13
			DATE MAILED	•

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed 6/18/01 is not fully responsive to the Office communication mailed 4/18/01 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

In particular, it is noted that the sequence presented in Claim 12 does not appear to be represented in either the CRF or Sequence Listing. In addition, it is unclear if all the sequences in the specification are represented in the CRF and Sequence Listing. For example, sequences of 4 or more amino acids/10 or more nucleotides are found AT LEAST on pages 8, lines 33-35; page 9, line 16; page 14, lines 15-18; page 15, lines 25-27; page 16, lines 29-35; page 22, lines 20-35; page 23, lines 34-35; and page 33, line 16. Applicant is requested to carefully review the specification to confirm that all sequences meeting the sequence rules are included in the CRF/Sequence Listing, and to amend the specification accordingly.

Since the reply appears to be <u>bona fide</u> attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE** (1) **MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Jessica Roark, Art Unit 1644, whose telephone number is (703) 605-1209.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

Jessica Roark, Ph.D. Art Unit 1644 Technology Center 1600 August 30, 2001

PHULIP GAMBEL, PHI PRIMARY EXAMINATION 1600 TELL CONTO 1600

Notice to Comply

Application No.	Applicant(s)			
09/524,531	IMHOF ET AL.			
Examiner	Art Unit			
Jessica H. Roark	1644			

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements

for	such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
\boxtimes	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
\boxtimes	7. Other: Sequence in claims and spec not found in CRF or Sequence listing; also IDs not inserted into spec.
	oplicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
_	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the ecification.
	A statement that the contest of the paper and computer readable papies are the same and where applicable, include

- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY